Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Edwards Lifesciences (EW) PT Raised to $136 at Jefferies Following Investor Day
December 8, 2017 6:50 AM ESTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $136.00 (from $132.00) while maintaining a Buy rating.
Analyst Raj Denhoy highlighted three conclusions from EWs annual investor briefing:
1. With efforts to tap less sick, undiagnosed, and untreated populations along with continued... More
Edwards Lifesciences (EW) PT Raised to $135 at Cowen
December 8, 2017 6:40 AM ESTCowen raised its price target on Edwards Lifesciences (NYSE: EW) to $135.00 (from $130.00) while maintaining a Outperform rating.
Analyst Joshua Jennings said EW's 2018 targets are likely conservative and were well received. Jennings said the update to the WW TAVR franchise leaves room for 2018 upside and... More
